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The primary headache disorders include migraine, which is one of the most frequent 
neurological disorders, which influences more than 14% of the whole population. Despite 
the research efforts, its exact pathomechanism is not fully revealed, but evidence points 
to the role of glutamate and its receptors. Kynurenic acid is an endogenous glutamate 
receptor antagonist produced by the kynurenine pathway (KP). Tryptophan 2,3-dioxy-
genase (TDO) and indoleamine 2,3-dioxygenase (IDO) convert l-tryptophan to N-formyl-
l-kynurenine, to be further transformed to l-kynurenine. Kynurenine aminotransferase-II 
(KAT-II), l-kynurenine hydrolase (KYNU), and l-kynurenine 3-monooxygenase (KMO) are 
key enzymes in the later steps of the KP. Nitroglycerin (NTG) administration serves as 
both human and animal model of migraine, causing the activation and sensitization in 
the trigeminal system. A previous study demonstrated a reduction of KAT-II expression 
following NTG administration in animals. The goal of current tests was to identify the 
potential modulatory effect of NTG on other metabolizing enzymes of the KP in the 
caudal trigeminal nucleus (TNC) of rats. Four hours following the intraperitoneal injection 
of NTG (10 mg/kg), the rats were perfused transcardially and the TNC was extracted 
for Western blotting. Western blot studies revealed that the expression of TDO2, IDO1, 
KYNU, and KMO decreased in the TNC. The results demonstrated that NTG is able to 
downregulate the KP, with a potential influence on the glutamatergic system as well, 
contributing to the development of trigeminal activation and sensitization in animals.
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inTrODUcTiOn
Migraine is a common primary headache characterized by severe head pain and numerous concomi-
tant symptoms, e.g., vomiting, nausea, photophobia, and phonophobia. The disease affects about 14% 
of the total population (1). The exact pathophysiology of the disorder is not fully understood, but it is 
Abbreviations: GAPDH, glyceraldehyde 3-phosphate dehydrogenase; IDO, indoleamine 2,3-dioxygenase; KAT-II, kynure-
nine aminotransferase-II; KMO, l-kynurenine 3-monooxygenase; KYNA, kynurenic acid; KYNU, l-kynurenine hydrolase; 
KP, kynurenine pathway; l-KYN, l-kynurenine; NMDA, N-methyl-d-aspartate; NO, nitric oxide; NTG, nitroglycerin; 
PBS, phosphate-buffered saline; QUIN, quinolinic acid; TBST, Tris-buffered saline containing Tween 20; TDO, tryptophan 
2,3-dioxygenase; TNC, caudal trigeminal nucleus; Trp, tryptophan.
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well known that the activation and sensitization of the trigeminal 
system is essential during the attack (2). Several lines of evidence 
have been put forth to support the hypothesis that glutamate recep-
tors, principally N-methyl-d-aspartate (NMDA) receptors, have a 
pivotal aspect in these phenomena (3). Kynurenic acid (KYNA) is 
a neuroprotective metabolite that interacts with glutamate recep-
tors, aryl hydrocarbon receptor, and G protein-coupled receptor 
35 and elicits anti-glutamatergic actions. Series of data confirm 
that KYNA and its analogs have anti-nociceptive effects in several 
migraine models (4–6), probably by attenuating the trigeminal 
activation and sensitization. The initial process in the kynure-
nine pathway (KP) is the transformation of tryptophan (Trp) to 
N-formyl-l-kynurenine by tryptophan 2,3-dioxygenase (TDO1, 
2) and indoleamine 2,3-dioxygenase (IDO1,2): the rate-limiting 
enzymes of Trp metabolism. N-formyl-l-kynurenine is further 
converted by formamidase to l-kynurenine (l-KYN), which is 
converted to KYNA by kynurenine aminotransferases (KATs), to 
3-hydroxykynurenine by l-kynurenine 3-monooxygenase (KMO), 
and to anthranilic acid by l-kynurenine hydrolase (KYNU). The 
other metabolite of the KP is quinolinic acid (QUIN). In contrast 
to KYNA, QUIN is an agonist of the NMDA receptors and can 
provoke neuronal death and also causes lipid peroxidation and 
generates reactive oxygen species (7, 8) (Figure 1).
Systemic administration of nitroglycerin (NTG) can be utilized 
as a human and animal model of migraine. NTG is enzymati-
cally converted to nitric oxide (NO) in the body, probably by a 
mitochondrial aldehyde dehydrogenase (9). The administration 
of NTG is able to activate and sensitize the trigeminal system 
in humans and animals (10–12). In our previous study, it was 
demonstrated that NTG decreased the expression of kynurenine 
aminotransferase-II (KAT-II) (13), which converts l-KYN to 
KYNA in the brain thus reducing KYNA levels, contributing to 
the hyperactivity of NMDA receptors.
The goal of this study was to explore the issue of NTG on the 
expression levels of TDO2, IDO1, KYNU, and KMO enzymes in 
the caudal trigeminal nucleus (TNC).
MaTerials anD MeThODs
animals
We followed the directives for the Use of Animals in Research of 
the International Association for the Study of Pain and the policy 
of the European Economic Community (86/609/ECC). They 
were authorized by the local ethical committee of University of 
Szeged and the Scientific Ethics Committee for Animal Research 
of the Protection of Animals Advisory Board (XXIV./352/2012). 
44 adult male Sprague-Dawley rats of 200–250 g bodyweight were 
used. The rodents were raised and maintained under standard 
laboratory conditions with tap water and regular rat chow avail-
able ad libitum on a 12 h dark–12 h light cycle.
Drug administration
The animals were separated into two groups (n = 5). The animals 
in the first group, called placebo group, received only the vehicle 
solution (physiological saline) as treatment. In the second group, 
the rats were treated with an intraperitoneal injection of NTG 
(10 mg/kg bodyweight, Pohl Boskamp).
Western Blot analysis
Four hours after the placebo/NTG injection, the animals were 
perfused transcardially with 100  mL phosphate-buffered saline 
and the dorsal horns of TNC segments (+1 and −5 mm from the 
obex) were extracted. The samples were stored at −80°C and they 
were sonicated in ice cold lysis buffer containing 50 mM Tris–HCl, 
150 mM NaCl, 0.1% igepal, 0.1% cholic acid, 2 µg/mL leupeptin, 
2 mM phenylmethylsulfonyl fluoride, 1 µg/mL pepstatin, 2 mM 
EDTA, and 0.1% sodium dodecyl sulfate. The homogenates were 
centrifuged for 10 min at 12,000 RPM at 4°C and supernatants were 
aliquoted and stored at −20°C until use. BCA Protein Assay Kit 
was used to measure protein concentration. Samples were mixed 
with sample buffer and were boiled for 3 min. Standard SDS poly-
acrylamide gel electrophoresis was performed with equal amounts 
of protein samples (20 μg/lane) loaded on 10% Tris–glycine gel and 
electrotransferred onto Amersham Hybond-ECL nitrocellulose 
membrane (0.45  µm pore size). Page Ruler Prestained Protein 
Ladder (10–170 kDa) was used to define approximate molecular 
weights. Non-specific binding was eliminated by blocking in Tris-
buffered saline containing Tween 20 (TBST) and 5% non-fat dry 
milk for 1 h at room temperature. Then, membranes were incu-
bated in TBST containing 1% non-fat dry milk and TDO antibody 
(LifeSpan BioSciences, LS-C111058, dilution: 1:500, incubation: 
overnight at room temperature), IDO antibody (Abcam, ab106134, 
dilution: 1:500, incubation: overnight at room temperature), 
KYNU antibody (Abcam, ab96365, dilution: 1:500, incubation: 
overnight at room temperature), KMO antibody (Abcam, ab83929, 
dilution: 1:4,000, incubation: overnight at room temperature), or 
glycerinaldehyde 3-phosphate dehydrogenase (GAPDH) antibody 
(Cell Signaling Technologies, 8884, dilution: 1:1,000, incubation: 
overnight at room temperature). On the following day, a horserad-
ish peroxidase-conjugated anti-rabbit secondary antibody (Santa 
Cruz Biotechnology, sc-2030) in TBST containing 1% non-fat dry 
milk was applied for 2 h at room temperature. SuperSignal West 
Pico Chemiluminescent Substrate was used to visualize bands on 
Carestream Kodak BioMax Light film. Western blot protocol was 
developed based on previous experiments (4, 14–16).
An observer blinded to the experimental groups carried out 
the measurements. The detailed methods were described previ-
ously (13).
Films were quantified by Java ImageJ 1.47v analysis software 
(National Institutes of Health). The data were standardized to 
GAPDH.
statistical analysis
Statistical analysis was carried out by SPSS Statistics software 
(Version 20.0 for Windows, SPSS Inc.). Normality was checked by 
Kolmogorov–Smirnov test, and group means were compared by 
independent t-test, with p < 0.05 taken as statistically significant. 
Group values are presented as means ± SEM.
resUlTs
nTg induced a Decrease in TDO2 
expression in the Tnc
TDO2 protein was identified at 50 kDa in Western blot assay. 
Densitometric analyses showed that the TDO2 bands were 
FigUre 1 | The kynurenine pathway.
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significantly decreased (p  <  0.05) in the TNC after NTG 
administration as correlated with the placebo-treated animals 
(Figure 2).
nTg Treatment resulted in a Diminished 
iDO1 expression
A band characteristic of the IDO1 protein was referred at 45 kDa 
in Western blot assay. Densitometric analyses confirmed that the 
IDO1 bands were significantly weaker (p <  0.05) in the TNC 
after NTG administration as correlated with the placebo-treated 
animals (Figure 3).
nTg Was able to reduce the expression 
of KYnU
We could determine a band at 35  kDa characteristic for the 
KYNU protein. In animals, which had received NTG, the density 
FigUre 3 | Western blot of IDO1 and GAPDH expression in the TNC. The quantitative analysis shows that in the NTG group, the relative optical density  
of IDO1-specific bands was significantly decreased compared with the placebo group. *p < 0.05; GAPDH, glyceraldehyde 3-phosphate dehydrogenase;  
IDO1, indoleamine 2,3-dioxygenase; NTG, nitroglycerin; TNC, caudal trigeminal nucleus.
FigUre 2 | Western blot analysis of TDO2 and GAPDH protein from the TNC. The quantitative analysis shows that in the NTG group the relative optical density  
of TDO2 specific bands were significantly less pronounced compared with the placebo group. *p < 0.05; GAPDH, glyceraldehyde 3-phosphate dehydrogenase;  
NTG, nitroglycerin; TDO2, tryptophan 2,3-dioxygenase 2; TNC, caudal trigeminal nucleus.
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of KYNU protein bands was weaker in TNC segments (p < 0.05) 
as compared with the placebo-treated group (Figure 4).
KMO expression Was lower after nTg 
administration
l-Kynurenine 3-monooxygenase protein was identified at 56 kDa 
in Western blot assay. Densitometric analyses showed that the 
KMO bands were significantly decreased (p < 0.05) in segments 
TNC after NTG administration as correlated with the placebo-
treated animals (Figure 5).
DiscUssiOn
The current data demonstrated that NTG is able to decrease 
the expression of the KP enzymes in rat TNC. However, the 
question arises how NTG/NO can influence the KP. It is well 
known that the nitrergic system is able to alter the KP, e.g., NO 
can inhibit IDO expression via reversible binding to the active 
site in macrophages (17) and IDO activity is downregulated by 
NO production in bone marrow cells (18). The other hand, it is 
also known that the expression of KMO influences NO produc-
tion in human HEK293 cells (19). Moreover, Backhaus and her 
colleagues showed in a mass spectrometry and NMR study that 
there is a direct interaction between kynurenine metabolites 
(e.g., 3-hydroxykynurenine and 3-hydroxyanthranilic acid) and 
NO (20).
It is also important to note that kynurenines have a crucial 
role in immune regulation (21). The transcriptional expression 
of IDO, KMO, and KYNU is also under the control of interferons 
(21), thus pro-inflammatory cytokines influence KP (22). Lögters 
and co-workers have shown that the ratio of kynurenine– 
tryptophan was increased in the blood of patients with post-
traumatic sepsis (23), which pointed out that inflammation could 
modulate KP.
In this context, it is crucial that NO may cause neurogenic 
inflammation in the central nervous system. This is supported 
by observations that NTG was able to increase the expression 
of nuclear factor κB in the trigeminocervical complex of rats 
(13, 24), which is a key player in the inflammation process con-
trolled by cytokines. In human studies, Tfelt-Hansen and his group 
demonstrated that infusion of NTG can trigger inflammatory 
FigUre 5 | Illustrative Western blot bands and diagram of KMO and GAPDH in the TNC. The quantitative analysis shows that in the NTG group, the relative  
optical density of KMO specific bands was significantly weaker compared with the placebo group. *p < 0.05; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; 
KMO, l-kynurenine 3-monooxygenase; NTG, nitroglycerin; TNC, caudal trigeminal nucleus.
FigUre 4 | Representative Western blot bands and diagram of KYNU and GAPDH in the TNC. The quantitative analysis shows that in the NTG group, the relative 
optical density of KYNU-specific bands were significantly smaller compared with the placebo group. *p < 0.05; GAPDH, glyceraldehyde 3-phosphate 
dehydrogenase; KYNU, kynurenine hydrolase; NTG, nitroglycerin; TNC, caudal trigeminal nucleus.
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response by inducing inflammatory mediators, which response 
was inhibited by the anti-inflammatory drug, prednisolone (25).
In the previous study, we demonstrated that NTG was able to 
decrease the expression of KAT-II, which produces KYNA. Our 
present and earlier Western blot data showed that NTG could 
reduce the expression levels of the KP enzymes.
Our findings are comparable with recent studies, which 
showed that the chronic migraine and cluster headaches are asso-
ciated with altered levels of kynurenine metabolites, i.e., reduced 
levels of KYNA and l-KYN have been found in the serum of 
these patients (26, 27). These findings are in accordance with the 
theory of an increased release of glutamate probably yielding to a 
hyperactivity of glutamate receptors.
Migraine can be characterized by an increase in glutamatergic 
function (28), yielding fully activated NMDA receptors by the 
high glutamate levels, which might combine with small KYNA 
levels. Increased glutamate levels were found in the human 
cerebrospinal fluid, platelets, and plasma of migraine sufferers 
(29, 30).
To summarize the human and animal data, we can conclude 
that the KP is downregulated under the different types of head-
aches and thus possibly providing less KYNA. These data are in 
line with the theory of hyperactive NMDA receptors having a 
crucial role in the migraine pathophysiology. These receptors 
are key players in the mechanism of central sensitization (31), 
which have a pivotal role in the pathophysiology of migraine. Our 
present data strongly confirm that the KP has a relevant role in the 
pathomechanism of the trigeminal activation and sensitization, 
thus in the migraine pathology as well. In summary, influencing 
the KP provides a possible new target in the future therapy of 
migraine.
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